RIYADH: UAE sovereign wealth fund Mubadala Investment Co. has acquired 100 percent ownership of UCB Pharma’s mature business in China, in partnership with CBC Group, a healthcare-focused asset manager.  Belgium-based UCB, a global biopharma firm, has a presence in China’s growing immunology and neurology markets.  Mubadala did not disclose the size of its stake or the value of the transaction, which is expected to close in the fourth quarter of 2024.